Nov 11, 2022 / 04:10PM GMT
Tyler Van Buren - Cowen, Inc. - Analyst
All right. Good morning or good afternoon, everyone. My name is Tyler Van Buren, and I'm a Senior Biotech analyst at Cowen. Thank you for joining us for Cowen's Sixth Annual IO Next Summit. For this next session, I'll be moderating a fireside chat with Allogene Therapeutics, a leader and pioneer in the AlloCell therapy space. It's my pleasure to introduce my friend, Eric Schmidt, Allogene's Chief Financial Officer. Eric, thank you for taking the time with us today.
Eric Schmidt - Allogene Therapeutics, Inc. - CFO
Thank you, Tyler. Thanks to Cowen for hosting. Always a pleasure.
Questions and Answers:
Tyler Van Buren - Cowen, Inc. - Analyst(Conference Instructions) Eric, let's go ahead and kick it off with a couple general questions. So the CD19 class of CAR T is annualizing at $2 billion and growing at a significant pace with recent second-line approvals. And then the BCMA class of CAR Ts is launching and will likely create another multibillion class of CAR T. So what's
Trustpilot
